Medizinische Universitaet Innsbruck

Innsbruck, Austria

8 recruiting

Showing 112 of 12 trials

Recruiting
Phase 2Phase 3

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Breast Neoplasms
Bristol-Myers Squibb500 enrolled294 locationsNCT06926868
Recruiting
Phase 3

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Amgen304 enrolled192 locationsNCT04994717
Recruiting
Phase 3

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

GlioblastomaGBMRecurrent Glioblastoma
CarThera560 enrolled48 locationsNCT05902169
Recruiting
Phase 3

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's DiseaseObesity or Overweight
Eli Lilly and Company290 enrolled187 locationsNCT06937099
Recruiting
Phase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ulcerative ColitisObesity or Overweight
Eli Lilly and Company350 enrolled191 locationsNCT06937086
Recruiting
Phase 3

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,080 enrolled260 locationsNCT07213804
Recruiting
Phase 2Phase 3

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Urothelial Cancer
Bristol-Myers Squibb470 enrolled160 locationsNCT07106762
Recruiting
Phase 1

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Non-small Cell Lung CancerThoracic Tumors
Amgen500 enrolled83 locationsNCT06333951
Recruiting
Phase 3

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Multiple Myeloma
European Myeloma Network B.V.1,594 enrolled211 locationsNCT05243797
Recruiting
Phase 3

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intellia Therapeutics1,200 enrolled132 locationsNCT06128629
Recruiting
Phase 3

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Metastatic Castration-resistant Prostate Cancer
Amgen675 enrolled164 locationsNCT06691984
Recruiting
Phase 3

STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant
University of Cologne420 enrolled27 locationsNCT07280585